Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients
Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients
复制标题
DOI：
10.1002/ijc.11052
复制
发表时间：
2003-06-10
影响因子：
6.4
通讯作者：
Keilholz, U
中科院分区：
文献类型：
--
作者：
Nagorsen, D;Scheibenbogen, C;Keilholz, U
越来越多的证据表明，肿瘤在相当大比例的患者中引起特异性T细胞应答。最近，我们已经表明，在患有结直肠癌的患者中，针对肿瘤相关抗原（TAA）Ep-CAM、her-2/neu或CEA的特异性T细胞可以使用IFN γ-ELISPOT测定法在外周血中检测到。在我们的研究中，我们分析了乳腺癌和结直肠癌患者外周血中针对这些TAA的HLA-A*0201限制性表位的T细胞应答。令人惊讶的是，在20例乳腺癌患者中发现完全不存在针对这些TAA的离体T细胞应答。相比之下，在49例结直肠癌患者中的12例中可检测到针对至少1种TAA的特异性T细胞，证实了我们先前的结果。在两种恶性肿瘤中，针对流感衍生肽的T细胞应答相似。我们的研究结果表明，乳腺癌和结直肠癌患者之间的肿瘤免疫原性或肿瘤特异性T细胞的迁移模式存在差异。本文报道的研究结果对抗原特异性T细胞疗法的发展具有影响。(C)2003 Wiley-Liss，Inc.
There is increasing evidence that tumors elicit specific T-cell responses in a substantial proportion of patients. Recently, we have shown that in patients with colorectal cancer specific T cells against the tumor-associated antigens (TAA) Ep-CAM, her-2/neu or CEA can be detected in peripheral blood using IFNgamma-ELISPOT assay. In our study, we have analyzed T-cell responses against HLA-A*0201-restricted epitopes of these TAA in peripheral blood of patients with breast cancer and colorectal cancer. Surprisingly, a complete absence of ex vivo T-cell responses against these TAA was found in 20 patients with breast cancer. In contrast, specific T cells were detectable in 12 of 49 patients with colorectal cancer against at least I of these TAA, confirming our previous results. T-cell responses against influenza-derived peptides were similar in both malignancies. The results of our study indicate a difference either of tumor immunogenicity or of the migratory pattern of tumor-specific T cells between breast cancer and colorectal cancer patients. The findings reported here have implications for the development of antigen-specific T-cell therapies. (C) 2003 Wiley-Liss, Inc.